Dr. Deol on the Safety of CAR T-Cell Therapy

Video

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Abhinav Deol, MD, associate professor with Karmanos Cancer Institute, discusses patient eligibility for chimeric antigen receptor (CAR) T-cell therapy in hematologic oncology.

Once a clinician determines a patient’s eligibility to receive CAR T-cell therapy, physicians watch for cytokine release syndrome (CRS) and neurological toxicities. In some mild cases, the CRS can be characterized by fevers, chills, and slightly low blood pressure that responds to intravenous fluids, explains Deol. However, extreme cases may manifest in high fevers and blood pressure that drops low enough to require medication.

In terms of neurological toxicity, some patients do not experience any. Other patients may have mild confusion. In severe cases, patients can become comatose or have seizures as a result of neurotoxicity. To date, the companies that produce the CAR T products have been very careful to only have sites that have experience and sufficient training treat patients, says Deol. They are limiting the first roll-out to sites that are able to manage these toxicities, because it is a multimodality management, adds Deol.

Related Videos
Sowmya Viswanathan, PhD, on Translating Cell Therapies to the Clinic at ISCT 2024
Omar Nadeem, MD, on Initial Efficacy of GPRC5D-CAR in R/R Multiple Myeloma
Omer A. Abdul Hamid, MD, on Improving Gene Therapy’s Effect and Accessibility
George Tachas, PhD, on Tackling DMD Treatment From Multiple Angles
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
© 2024 MJH Life Sciences

All rights reserved.